Open AccessSafety Profile of Treatment in Diabetic Peripheral Neuropathic Pain
Author(s) -
RobinsonPapp Jessica,
Simpson David M.
Publication year - 2007
Publication title -
pain medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 97
eISSN - 1526-4637
pISSN - 1526-2375
DOI - 10.1111/j.1526-4637.2007.00351.x
Subject(s) - medicine , duloxetine , pregabalin , neuropathic pain , regimen , anesthesia , peripheral neuropathy , food and drug administration , peripheral , safety profile , intensive care medicine , diabetes mellitus , surgery , pharmacology , alternative medicine , adverse effect , pathology , endocrinology
New treatment options for diabetic peripheral neuropathic pain (DPNP) have recently been developed, including two Food and Drug Administration (FDA) approved agents, duloxetine and pregabalin. As clinicians face a broader spectrum of efficacious treatments, side‐effect profiles play an increasingly important role in the development of a pain management regimen. In this article we review the safety profile of agents commonly used in the treatment of DPNP.